

2

Docket No. G-056US04CIP
Serial No. 09/978,360In the Claims

1 -13 (canceled).

14 (currently amended). A composition of matter comprising:

- a) an isolated polypeptide comprising from ~~6~~ 300 to 351 consecutive amino acids of SEQ ID NO: 437;
- ~~b) an isolated polypeptide comprising the signal peptide sequence of SEQ ID NO: 437;~~
- e) b) an isolated polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 437;
- ~~d) c)~~ an isolated polypeptide comprising SEQ ID NO: 437; ~~or~~
- d) an isolated polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO: 437; or
- e) an isolated polypeptide of a) through d) and a physiologically acceptable carrier.

15 (currently amended). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising from ~~6~~ 300 to 351 amino acids of SEQ ID NO: 437.

16 (canceled).

17 (previously presented). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 437.

18 (previously presented). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising SEQ ID NO: 437.

3

Docket No. G-056US04C1P
Serial No. 09/978,360

19 (previously presented). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

20. (previously presented). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

21 (canceled).

22 (currently amended). The composition of matter according to claim 14, wherein said composition of matter comprises an isolated polypeptide comprising from ~~6 to 500~~300 to 352 amino acids of SEQ ID NO: 437 and a pharmaceutically acceptable carrier.

23 (new-withdrawn). A method of making a polypeptide, said method comprising

- a) providing a population of host cells comprising a polynucleotide encoding a polypeptide according to claim 14;
- b) culturing said population of host cells under conditions conducive to the production of a polypeptide within said host cells; and
- c) purifying said polypeptide from said population of host cells.

24 (new-withdrawn). A method of binding a polypeptide of claim 14 to an antibody of comprising contacting said antibody with said polypeptide under conditions in which antibody can specifically bind to said polypeptide.

25. (new). The composition of matter according to claim 14, wherein said polypeptide exhibits a C₃HIC₄ sequence motif (the RING zinc finger signature).

4

Docket No. G-056US04CIP
Serial No. 09/978,360

26 (new). A composition of matter comprising a polypeptide comprising at least 37 consecutive amino acids of SEQ ID NO: 437 and exhibiting a C₃HC₄ sequence motif (the RING zinc finger signature).

27 (new). The composition of matter according to claim 26, wherein said polypeptide comprises amino acid positions 302 through 339 of SEQ ID NO: 437.

J:\G:\N056.US04.CIP\Amend-Resp\Amd 2d.doc\DNB/sl